Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAGOON
2024-513559-34-00Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin in small cell lung cancer (SCLC) (3 arms), sponsored by PharmaMar. Primary endpoint: Overall survival. Started Jul 2024; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-513559-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513559-34-00.